Advancing mRNA Therapies in Rare Ophthalmic Disorders: Lessons from Clinical Development
Time: 10:30 am
day: Conference Day Two
Details:
- Differentiate mRNA therapies from DNA-based gene therapies, highlighting unique opportunities and challenges in ocular indications
- Share lessons learned from rare disease trial execution, including patient population considerations and regulatory navigation
- Explore the role of novel and alternative endpoints in inherited retinal disorder studies to better capture efficacy
